Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics reported its FY2023 consolidated financial results, recording revenue of KRW 3.69T (+23.1% YoY) and operating profit of KRW 1.11T (+13.2% YoY).
📊 [Key Disclosure Details & Financial Figures]
- Disclosure Type: Change in Profit and Loss Structure (Unit: KRW Thousand)
- Consolidated Revenue: KRW 3,694,588,767 thousand (Prior FY: KRW 3,001,295,198 thousand, YoY +23.1%, Increase: KRW 693,293,569 thousand)
- Consolidated Operating Profit: KRW 1,113,680,010 thousand (Prior FY: KRW 983,627,394 thousand, YoY +13.2%, Increase: KRW 130,052,616 thousand)
- Profit Before Income Tax Expenses: KRW 1,119,986,931 thousand (Prior FY: KRW 1,009,024,574 thousand, YoY +11.0%, Increase: KRW 110,962,357 thousand)
- Consolidated Net Profit: KRW 857,691,298 thousand (Prior FY: KRW 798,056,210 thousand, YoY +7.5%, Increase: KRW 59,635,088 thousand)
- Financial Position (Consolidated):
- Total Assets: KRW 16,046,197,209 thousand (Prior FY: KRW 16,582,050,258 thousand)
- Total Liabilities: KRW 6,215,704,797 thousand (Prior FY: KRW 7,597,575,863 thousand)
- Total Equity: KRW 9,830,492,412 thousand (Prior FY: KRW 8,984,474,395 thousand)
- Capital Stock: KRW 177,935,000 thousand (Total Equity to Capital Stock Ratio: 5,524.8%)
- Separate Financial Data (Parent Company):
- Separate Revenue: KRW 2,938,755,681 thousand (Prior FY: KRW 2,437,286,112 thousand)
- Main Reasons for Changes in Profit/Loss Structure: Stable operation of Plants 1-3, successful ramp-up of Plant 4, and full-year consolidation of the consolidated subsidiary following its inclusion
- Board Resolution Date: January 24, 2024 (4 Outside Directors attended, 0 absent)
- Other Remarks:
- Samsung Bioepis was included as a consolidated subsidiary during Q2 2022 (accounted for via equity method until April 2022, consolidated from May 2022)
- Financial figures are preliminary prior to external audit completion and are subject to change
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Final Audit Figures and Subsequent Audit Report Disclosure
This disclosure provides preliminary financial results for FY2023 prior to external audit completion, reporting year-on-year changes in revenue and earnings under large corporation criteria. Checking whether these preliminary figures are confirmed without adjustments following the external audit is essential to evaluate the final accuracy and reliability of the reported financial data. Investors can verify the finalized figures and the auditor’s opinion through the upcoming ‘Submission of Audit Report’ filing and the Annual Report.
📢 Disclaimer and Source Notice
Source: This content was structured and newly generated based on official submission data from the Financial Supervisory Service DART system.
Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial liabilities rest entirely with the individual investor.
Contact: For regulatory compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
